The Management of Recurrent Ovarian Cancer

Bukowski, Ronald M.; Ozols, Robert F.; Markman, Maurie

doi:10.1053/j.seminoncol.2007.03.012

« PreviousSeminars in Oncology
Volume 34, Supplement 2 , Pages S1-S15, April 2007

The Management of Recurrent Ovarian Cancer

Ronald M. Bukowski
- The Cleveland Clinic Foundation Taussig Cancer Center and the Cleveland Clinic Foundation Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
- Dr Bukowski has received research grant support from Bristol-Myers Squibb and Eli Lilly and Company. Dr Ozols has served as a consultant to Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Novartis Pharmaceuticals, Telik, Inc, and Unither Pharmaceuticals, and has served on an advisory committee and as a speaker for Eli Lilly and Company. Dr Markman has served as a consultant to Celgene, Eli Lilly and Company, Genentech, GlaxoSmithKline, Merck & Co, Inc, Telik, Inc, and Tibotec Therapeutics.
- Address correspondence to Ronald M. Bukowski, MD, Experimental Therapeutics Program, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195
Robert F. Ozols
- Fox Chase Cancer Center, Philadelphia, PA.
- Dr Bukowski has received research grant support from Bristol-Myers Squibb and Eli Lilly and Company. Dr Ozols has served as a consultant to Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Novartis Pharmaceuticals, Telik, Inc, and Unither Pharmaceuticals, and has served on an advisory committee and as a speaker for Eli Lilly and Company. Dr Markman has served as a consultant to Celgene, Eli Lilly and Company, Genentech, GlaxoSmithKline, Merck & Co, Inc, Telik, Inc, and Tibotec Therapeutics.
Maurie Markman
- The University of Texas M. D. Cancer Center, Houston, TX.
- Dr Bukowski has received research grant support from Bristol-Myers Squibb and Eli Lilly and Company. Dr Ozols has served as a consultant to Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Novartis Pharmaceuticals, Telik, Inc, and Unither Pharmaceuticals, and has served on an advisory committee and as a speaker for Eli Lilly and Company. Dr Markman has served as a consultant to Celgene, Eli Lilly and Company, Genentech, GlaxoSmithKline, Merck & Co, Inc, Telik, Inc, and Tibotec Therapeutics.